· Published by Health Canada · Official notice
This is duplicated text of a letter from Merck Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 7, 2014
Subject: Association of TEMODAL® (temozolomide) with the risk of liver problems
Merck Canada Inc., in consultation with Health Canada, would like to inform you of new important safety information about TEMODAL® (temozolomide) and risk of liver problems.
TEMODAL® is an antitumor agent used in combination with radiotherapy in the treatment and maintenance therapy of some brain cancers.
Merck Canada Inc. has sent a letter to health care professionals informing them of this important safety information. You may view this letter on Health Canada's web site.
The TEMODAL® product information has been updated to include this new information. A copy may be obtained on the Merck Canada website or on the Health Canada web site.
If you have questions regarding your TEMODAL® prescription, please contact your doctor.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of serious liver injury or other serious or unexpected side effects in patients receiving TEMODAL® should be reported to Merck Canada Inc. or Health Canada.
Merck Canada Inc., Pharmacovigilance
16750 Trans-Canada Hwy.
Kirkland, Québec H9H 4M7
Fax: 1-800-369-3090
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Mauricio Ede, M.D.
Executive Director, Medical Affairs
® Registered trademark of Schering-Plough Canada Inc. Used under license.